NDC 70594-075-01 - MEROPENEM
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70594-075
- Requested NDC
- 70594-075-01
- Package NDCs from labels
- 70594-075-01, 70594-075-02
- Manufacturer
- Xellia Pharmaceuticals USA LLC
- Effective date
- 2024-07-10
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| MEROPENEM - Xellia Pharmaceuticals USA LLC | Xellia Pharmaceuticals USA LLC | 2024-07-10 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70594-075-01 | MEROPENEM | 1 in 1 VIAL, GLASS | INJECTION, POWDER, FOR SOLUTION | 1 | 7 | |
| 70594-075-02 | MEROPENEM | 10 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 10 | 7 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70594-075-01 | EA - Each | 70594-075 | 6b66b112-d7e1-45e3-9ecd-f451e089876d | 1 | 2021-09-07 |
| 70594-075-02 | EA - Each | 70594-075 | 06584bf5-011f-40ee-97f3-0eff9f3e1faf | 1 | 2021-09-07 |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Meropenem | MEROPENEM | Sagent Pharmaceuticals | e8848f4a-bca9-4978-b0a1-38483fd4d639 | 2026-03-31 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| VABOMERE | MEROPENEM-VABORBACTAM | Melinta Therapeutics, LLC | e237fd0f-3050-42a3-b43e-b6fb4824e93d | 2026-02-27 | Warnings, Adverse reactions | FV9J3JU8B1 |
| Meropenem | MEROPENEM | WG Critical Care, LLC | 240325ba-47a8-4ad1-bcab-6772069ee790 | 2026-01-08 | Warnings, Adverse reactions | FV9J3JU8B1 |
| Meropenem | MEROPENEM | BluePoint Laboratories | ca5f501c-6520-4d09-aae2-4f5db74d468f | 2025-12-12 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| MEROPENEM | MEROPENEM | Savior Lifetec Corporation | 31dd2160-7dbd-51fa-e054-00144ff88e88 | 2025-11-24 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| MEROPENEM | MEROPENEM | Sandoz Inc | 0d37e43b-ff8d-495d-b9af-4fd5fce53d56 | 2025-11-14 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Qilu Antibiotics Pharmaceutical Co., Ltd. | 1f9591ed-3a6c-422e-b1be-7b3e4fe5bf3c | 2025-09-16 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Civica, Inc. | 35466216-55ed-4836-8cbc-c8aafb079dae | 2025-09-12 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| MEROPENEM | MEROPENEM | Civica, Inc | b0075b72-c3cc-f844-e053-2a95a90a417f | 2025-09-10 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem and Sodium Chloride | MEROPENEM AND SODIUM CHLORIDE | B. Braun Medical Inc. | 3b952a55-6ef7-45c8-be21-16eefe37ec2e | 2025-08-05 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | BROOKS STERISCIENCE LIMITED | 58e165b7-e230-4459-abf9-06d5ca1dd7b2 | 2025-07-31 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Eugia US LLC | bf1d3433-9e3f-40a0-8bff-c8ceaa8bab7c | 2025-07-16 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Gland Pharma Limited | 4e4e2c0c-df54-4229-ab90-fa671ecedd57 | 2025-06-26 | Warnings, Adverse reactions | ANDA206141 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Amneal Pharmaceuticals LLC | a456013b-b20e-4b29-b2f9-06f18f1ea6bd | 2025-06-09 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Hikma Pharmaceuticals USA Inc. | d54fdbad-ca93-467c-92d7-c1bd88f3bbe3 | 2024-12-31 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Hospira, Inc. | e9b6555f-20a1-4415-bb80-3d034cfab95b | 2024-11-06 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | Hospira, Inc. | 092ebd9b-77a0-4877-afc3-dd8211730f71 | 2024-11-06 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| MEROPENEM | MEROPENEM | Xellia Pharmaceuticals USA LLC | 06d84c55-94ff-46e5-8477-b8881c12eb0a | 2024-07-10 | Warnings, Adverse reactions | ANDA206141 70594-076-01 70594-075-01 70594-076-02 70594-075-02 70594-075 70594-076 70594007501 1722934 1722939 3ee484ef-4e7f-464a-ac2e-7963d9dc5df6 06d84c55-94ff-46e5-8477-b8881c12eb0a FV9J3JU8B1 |
| Meropenem | MEROPENEM | ARMAS PHARMACEUTICALS INC | e1122310-c3ed-42f1-b189-301c221ff1f0 | 2022-07-29 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |
| Meropenem | MEROPENEM | WG Critical Care, LLC | 6520ae3d-e149-499c-8152-36f6ab861662 | 2021-06-30 | Warnings, Adverse reactions | 1722934 1722939 FV9J3JU8B1 |